TRULICITY Dulaglutide Injection Recalled for Temperature Abuse During Distribution
Cardinal Health Inc. recalls one lot of TRULICITY (dulaglutide) injection due to temperature abuse. The product was exposed to temperatures outside the manufacturer's labeled storage conditions.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for temperature-compromised medication. While no illnesses or injuries have been reported, temperature abuse of an injectable prescription drug represents a risk of harm, as the medication may be degraded or ineffective.
Plain-English summary
Cardinal Health Inc. is recalling one lot of TRULICITY (dulaglutide) injection, 0.75 mg/0.5mL, in 4 single-dose pens. The product was exposed to temperatures outside the manufacturer's labeled storage conditions.
The affected lot number is D484557A with an expiration date of 10/25/2023. Distribution was limited to New Mexico. TRULICITY is a once-weekly injectable prescription medication.
The FDA classified this as a Class II recall and assigned recall number D-0884-2022. Patients who received this lot should contact their healthcare provider or pharmacy regarding the recalled product.
The recalled product
- Product
- TRULICITY (DULAGLUTIDE)
- Brand
- TRULICITY
- Manufacturer
- Cardinal Health Inc.
- Category
- Drug
- Hazard
- temperature-abuse
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: D484557A
- Exp: 10/25/2023.
Distribution
Distributed in 1 state:
- NM
Related recalls
Same brand · TRULICITY
- SevereTrulicity autoinjector pens recalled for incorrect strength labeling
FDA (Drugs) · 2021-09-01
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27